These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26900984)

  • 21. Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.
    Ghanem S; Hassan S; Saad R; Dbaibo GS
    Expert Opin Biol Ther; 2013 Aug; 13(8):1197-205. PubMed ID: 23815506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: systematic review and meta-analysis.
    Pellegrino P; Perrone V; Radice S; Capuano A; Clementi E
    Pharmacol Res; 2015 Feb; 92():31-9. PubMed ID: 25447792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.
    Knuf M; Kieninger-Baum D; Habermehl P; Muttonen P; Maurer H; Vink P; Poolman J; Boutriau D
    Vaccine; 2010 Jan; 28(3):744-53. PubMed ID: 19887137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Miller JM
    Vaccine; 2015 Feb; 33(7):933-41. PubMed ID: 25152325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.
    Quiambao B; Peyrani P; Li P; Cutler MW; Van Der Wielen M; Perez JL; Webber C
    Hum Vaccin Immunother; 2020 Jun; 16(6):1272-1279. PubMed ID: 32401600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
    Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
    Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
    Borja-Tabora C; Montalban C; Memish ZA; Van der Wielen M; Bianco V; Boutriau D; Miller J
    BMC Infect Dis; 2013 Mar; 13():116. PubMed ID: 23510357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children.
    Klein NP; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
    Pediatr Infect Dis J; 2016 Jun; 35(6):662-72. PubMed ID: 26928521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
    Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
    Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
    Serra L; Webber C; Burman C; Bueti P; Gorruso M; Mather S
    Vaccine; 2022 Nov; 40(49):7014-7021. PubMed ID: 36283896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.
    Gasparini R; Tregnaghi M; Keshavan P; Ypma E; Han L; Smolenov I
    Pediatr Infect Dis J; 2016 Jan; 35(1):81-93. PubMed ID: 26398743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents.
    Serra LC; York LJ; Balmer P; Webber C
    J Adolesc Health; 2018 Sep; 63(3):269-279. PubMed ID: 30236996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12-23 months in China.
    Hu J; Li H; Chu K; Liang Q; Li J; Luo L; Hu Y; Meng F; Zhu F
    Hum Vaccin Immunother; 2019; 15(12):2952-2959. PubMed ID: 31348731
    [No Abstract]   [Full Text] [Related]  

  • 35. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.
    Arguedas A; Soley C; Loaiza C; Rincon G; Guevara S; Perez A; Porras W; Alvarado O; Aguilar L; Abdelnour A; Grunwald U; Bedell L; Anemona A; Dull PM
    Vaccine; 2010 Apr; 28(18):3171-9. PubMed ID: 20189491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants.
    Martinón-Torres F; Serra L; Safadi MAP
    Expert Rev Vaccines; 2020 Apr; 19(4):313-325. PubMed ID: 32250710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents.
    Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Han L; Smolenov I; Dull P
    Pediatr Infect Dis J; 2015 Oct; 34(10):e264-78. PubMed ID: 26135245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.